Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
US Patent Number
7816497
Publication Date
10-19-2010
Abstract
Activated C3 (C3a) and its receptor (C3aR) and activated C5 (C5a) and its receptor (C5aR) have been shown to induce vascular endothelial growth factor (VEGF) expression in vitro and in vivo. Compositions and methods for inhibiting C3a, C3aR, C5a and C5aR for the treatment and/or prevention of neovascular disease are provided. Also provided are Novel therapeutic targets and diagnostic markers for choroidal neovascularization.
Assignees
University of Kentucky, Lexington, KY (US)
Application Number
11/199,374
Filing Date
08/09/2005
Recommended Citation
Ambati, Jayakrishna, "Compositions and Methods for Inhibiting Drusen Complement Components C3a and C5a for the Treatment of Age-Related Macular Degeneration" (2010). Ophthalmology and Visual Science Faculty Patents. 18.
https://uknowledge.uky.edu/ophthalmology_patents/18
